Financial Feasibility Analysis of P-REC and T-REC by ALLCURE Inc
VerifiedAdded on 2023/06/03
|16
|2933
|429
AI Summary
The report presented here deals with the financial feasibility analysis of a drug product being considered for development by ALLCURE Inc. The results of the analysis depicts that the production of P-REC would be beneficial for the company if the discount rate happens to be 18%. The NPV of the product at this rate is $972,011.71 with the payback period of 5.51 years. However, if the discount rate increases to 24%, then it would be more beneficial for the company to go for alternative product T-REC in place of P-REC.
Contribute Materials
Your contribution can guide someone’s learning journey. Share your
documents today.